MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback